用于骨髓瘤治疗的嵌合抗原受体T细胞疗法正在推进中。
CARTs on the road for myeloma.
作者信息
Maus Marcela V, June Carl H
机构信息
Translational Research Program, Abramson Cancer Center; Departments of Medicine and.
Translational Research Program, Abramson Cancer Center; Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
出版信息
Clin Cancer Res. 2014 Aug 1;20(15):3899-901. doi: 10.1158/1078-0432.CCR-14-0721. Epub 2014 Jun 11.
Abstract
Chimeric antigen receptors redirect T cells to surface antigens. Discovery and validation of appropriate target antigens expands the possible indications for chimeric-antigen receptor (CAR) T cells. CS1 is expressed at high levels by multiple myeloma cells, but also to some extent on other lymphocytes. CS1 may be a viable target for CAR T cells in multiple myeloma.
摘要
嵌合抗原受体可将T细胞重定向至表面抗原。合适靶抗原的发现与验证拓展了嵌合抗原受体（CAR）T细胞的可能适应症。CS1在多发性骨髓瘤细胞中高水平表达，但在其他淋巴细胞上也有一定程度的表达。CS1可能是多发性骨髓瘤中CAR T细胞的一个可行靶点。
相似文献
1
CARTs on the road for myeloma.用于骨髓瘤治疗的嵌合抗原受体T细胞疗法正在推进中。
Clin Cancer Res. 2014 Aug 1;20(15):3899-901. doi: 10.1158/1078-0432.CCR-14-0721. Epub 2014 Jun 11.
2
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.对靶向CS1的T细胞进行基因改造可增强对骨髓瘤细胞的清除。
Clin Cancer Res. 2014 Aug 1;20(15):3989-4000. doi: 10.1158/1078-0432.CCR-13-2510. Epub 2014 Mar 27.
3
Zoom Zoom: racing CARs for multiple myeloma.Zoom Zoom：多发性骨髓瘤的赛车。
Clin Cancer Res. 2013 Apr 15;19(8):1917-9. doi: 10.1158/1078-0432.CCR-13-0168. Epub 2013 Feb 26.
4
A compound chimeric antigen receptor strategy for targeting multiple myeloma.靶向多发性骨髓瘤的嵌合抗原受体复合策略。
Leukemia. 2018 Feb;32(2):402-412. doi: 10.1038/leu.2017.302. Epub 2017 Sep 27.
5
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.B 细胞成熟抗原是多发性骨髓瘤过继性 T 细胞治疗的一个有前途的靶点。
Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.
6
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.CS1 特异性嵌合抗原受体（CAR）修饰的自然杀伤细胞增强了针对人多发性骨髓瘤的体外和体内抗肿瘤活性。
Leukemia. 2014 Apr;28(4):917-27. doi: 10.1038/leu.2013.279. Epub 2013 Sep 26.
7
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.双特异性嵌合抗原受体 T 细胞治疗多发性骨髓瘤。
Cancer Immunol Res. 2020 Dec;8(12):1485-1495. doi: 10.1158/2326-6066.CIR-20-0118. Epub 2020 Oct 2.
8
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.嵌合抗原受体修饰 T 细胞疗法在多发性骨髓瘤中的应用：超越 B 细胞成熟抗原。
Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019.
9
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.嵌合抗原受体（CAR）疗法治疗多发性骨髓瘤。
Br J Haematol. 2016 Mar;172(5):685-98. doi: 10.1111/bjh.13889. Epub 2016 Jan 20.
10
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
引用本文的文献
1
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.mRNA-LNP 制备的 CAR-NK 细胞在体外和体内杀伤肿瘤靶细胞。
Int J Mol Sci. 2023 Aug 29;24(17):13364. doi: 10.3390/ijms241713364.
2
Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with Zirconium oxine for PET imaging.放射性核素标记奥昔美辛标记嵌合抗原受体修饰的 T 细胞用于 PET 成像后 scFv-IL-13Rα2 的鉴定。
J Transl Med. 2023 Jun 7;21(1):367. doi: 10.1186/s12967-023-04142-2.
3
Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging.用89锆草氨酸进行放射性标记用于PET成像后表达scFv-IL-13Rα2的嵌合抗原受体修饰T细胞的表征。
Res Sq. 2023 Jan 13:rs.3.rs-2242559. doi: 10.21203/rs.3.rs-2242559/v1.
4
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.BCL2-BH4拮抗剂BDA-366抑制人骨髓瘤生长。
Oncotarget. 2016 May 10;7(19):27753-63. doi: 10.18632/oncotarget.8513.
5
Multiple myeloma in the marrow: pathogenesis and treatments.骨髓中的多发性骨髓瘤：发病机制与治疗
Ann N Y Acad Sci. 2016 Jan;1364(1):32-51. doi: 10.1111/nyas.13038.
6
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.多发性骨髓瘤中的免疫反应：天然免疫监视的作用及免疫疗法的潜力
Cell Mol Life Sci. 2016 Apr;73(8):1569-89. doi: 10.1007/s00018-016-2135-z. Epub 2016 Jan 22.
7
Targeting B-cell maturation antigen in multiple myeloma.靶向多发性骨髓瘤中的B细胞成熟抗原
Immunotherapy. 2015;7(11):1187-99. doi: 10.2217/imt.15.77. Epub 2015 Sep 15.
8
Immune Modulation in Hematologic Malignancies.血液系统恶性肿瘤中的免疫调节
Semin Oncol. 2015 Aug;42(4):617-25. doi: 10.1053/j.seminoncol.2015.05.009. Epub 2015 Jun 3.
9
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.热休克蛋白90抑制剂可增强黑色素瘤上的抗原表达，并增加T细胞对肿瘤细胞的识别。
PLoS One. 2014 Dec 12;9(12):e114506. doi: 10.1371/journal.pone.0114506. eCollection 2014.
本文引用的文献
1
Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.对靶向CS1的T细胞进行基因改造可增强对骨髓瘤细胞的清除。
Clin Cancer Res. 2014 Aug 1;20(15):3989-4000. doi: 10.1158/1078-0432.CCR-13-2510. Epub 2014 Mar 27.
2
Adoptive immunotherapy for cancer or viruses.用于癌症或病毒的过继性免疫疗法。
Annu Rev Immunol. 2014;32:189-225. doi: 10.1146/annurev-immunol-032713-120136. Epub 2014 Jan 9.
3
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.依洛珠单抗通过与 CS1 配体结合直接增强 NK 细胞对骨髓瘤的细胞毒性：增强 NK 细胞功能补充 ADCC 的证据。
Cancer Immunol Immunother. 2013 Dec;62(12):1841-9. doi: 10.1007/s00262-013-1493-8. Epub 2013 Oct 26.
4
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.CS1 特异性嵌合抗原受体（CAR）修饰的自然杀伤细胞增强了针对人多发性骨髓瘤的体外和体内抗肿瘤活性。
Leukemia. 2014 Apr;28(4):917-27. doi: 10.1038/leu.2013.279. Epub 2013 Sep 26.
5
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.依洛珠单抗联合来那度胺和低剂量地塞米松治疗复发或难治性多发性骨髓瘤。
J Clin Oncol. 2012 Jun 1;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649. Epub 2012 Apr 30.
6
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.抗 CS1 单克隆抗体依鲁替尼联合硼替佐米治疗复发/难治性多发性骨髓瘤的 I 期临床试验。
J Clin Oncol. 2012 Jun 1;30(16):1960-5. doi: 10.1200/JCO.2011.37.7069. Epub 2012 Jan 30.
7
Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression.活体成像揭示了自然杀伤细胞和 CD8(+)T 细胞在肿瘤消退过程中的不同动力学。
Immunity. 2010 Oct 29;33(4):632-44. doi: 10.1016/j.immuni.2010.09.016. Epub 2010 Oct 14.
8
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.嵌合抗原受体识别 ERBB2 的 T 细胞给药后严重不良事件的病例报告。
Mol Ther. 2010 Apr;18(4):843-51. doi: 10.1038/mt.2010.24. Epub 2010 Feb 23.
9
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.CS1，一种用于治疗多发性骨髓瘤的潜在新型治疗性抗体靶点。
Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246.
10
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.抗CS1人源化单克隆抗体HuLuc63在骨髓微环境中抑制骨髓瘤细胞黏附并诱导抗体依赖性细胞毒性。
Blood. 2008 Aug 15;112(4):1329-37. doi: 10.1182/blood-2007-08-107292. Epub 2007 Sep 28.
Zotero 插件